Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Nevi

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    Query did not match any clinical trials.
    These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records.
    Study title: A clinical trial with Solcoderm, Haim S., Cohen A., 1983, Publication: Solcoderm treatment of epidermal growths including intradermmal nevi, 1984
    Active substance: ACETIC ACID_OXALIC ACID_NITRIC ACID_LACTIC ACID_COPPER (II) NITRATE
    Study summary document link (including results):
    View full study record
    Document reference: 21254
    Study title: 1 Month Oral (Gavage) Toxicity and Toxicokinetic Study in the Neonatal Sprague Dawley Rat, Followed by a 3 Month Recovery Period. AstraZeneca R&D Södertälje, Safety Assessment, Sweden (Charles River Laboratories Preclinical Services Montreal Inc, Sennevi
    Active substance: ESOMEPRAZOLE
    Study summary document link (including results):
    View full study record
    Document reference: 26609
    Study title: 1 Month Oral (Gavage) Toxicity and Toxicokinetic Study in the Neonatal Sprague Dawley Rat. AstraZeneca R&D Södertälje, Safety Assessment, Sweden (Charles River Laboratories Preclinical Services Montreal Inc, Senneville, Canada). May 2006.
    Active substance: ESOMEPRAZOLE
    Study summary document link (including results):
    View full study record
    Document reference: 26622
    Study title: A 3-Month Oral (Gavage) Toxicity and Toxicokinetic Study in the Neonatal Beagle Dog (a Second Complementary Study). AstraZeneca R&D Södertälje, Safety Assessment, Sweden (Charles River Laboratories Preclinical Services Montreal Inc, Senneville, Canada).
    Active substance: ESOMEPRAZOLE
    Study summary document link (including results):
    View full study record
    Document reference: 26611
    Study title: Open-label, multicenter trial of Magnevist® enteral in magnetic resonance imaging of patients
    Active substance: GADOPENTETIC ACID
    Study summary document link (including results): ME90095 ME91005 ME91006.pdf
    View full study record
    Document reference: 28825
    Study title: A Prospective Blinded Read to Explore the Efficacy of MULTIHANCE and MAGNEVIST (0.10 mmol/kg) in Magnetic Resonance Imaging (MRI) of Brain and Spine Tumors in Pediatric Population
    Active substance: FUSIDIC ACID
    Study summary document link (including results):
    View full study record
    Document reference: 28722
    Study title: Contrast Enhanced Magnetic Resonance Imaging of the Central Nervous System in Patients Between 2 and 18 Years of Age by Intravenous Administration: A Randomized Double-Blind Comparison of Gadodiamide Injection (Gd DTPA BMA) 0.1 mmol/kg with MAGNEVIST®(G d DTPA) 0.1 mmol/kg
    Active substance: GADODIAMIDE
    Study summary document link (including results): SW1357 Redacted.pdf
    View full study record
    Document reference: 47577
    Study title: Contrast Enhanced Magnetic Resonance Imaging of the Central Nervous System in Patients Between 2 and 18 Years of Age by Intravenous Administration: A Randomized Double-Blind Comparison of Gadodiamide Injection (Gd DTPA BMA) 0.1 mmol/kg with MAGNEVIST® (Gd DTPA) 0.1 mmol/kg (Protocol 50678-005, Study B)
    Active substance: GADODIAMIDE
    Study summary document link (including results): SW1358 Redacted.pdf
    View full study record
    Document reference: 47578
    Study title: A phase III, double-blind, parallel-group, randomized, comparative, two-centre study on gadodiamide injection (Omniscan) and Magnevist® at 0.1 mmol/kg b.w. in MR examinations of the CNS in children and adolescents in a 0.5 T Philips Gyroscan MR unit at the University Hospital Eppendorf, Hamburg, Germany, and in a 1.5T Philips Gyroscan S15 MR unit at the Department of Diagnostic Radiology, University of Cologne, Cologne, Germany
    Active substance: GADODIAMIDE
    Study summary document link (including results): SOV033 Redacted.pdf
    View full study record
    Document reference: 47574
    Study title: An open, multicenter clinical trial of Magnevist® in newborns and infants up to the second year of life in CNS indications
    Active substance: GADOPENTETIC ACID
    Study summary document link (including results): Bayer Pharma_Gadopentetate Dimeglumine_90104_study_synopsis.pdf
    View full study record
    Document reference: 28833
    Study title: Eur Radiol. 1998;8(6):1054-7. Myelography with a dimeric (iodixanol) and a monomeric (iohexol) contrast medium: a clinical multicentre comparative study. Skalpe IO, Bonneville JF, Grane P, Gyldenstedt C, Otto B, Kristoffersen DT, Svaland MG. Eur Radiol. 1998;8(6):1054-7. Myelography with a dimeric (iodixanol) and a monomeric (iohexol) contrast medium: a clinical multicentre comparative study. Skalpe IO, Bonneville JF, Grane P, Gyldenstedt C, Otto B, Kristoffersen DT, Svaland MG.
    Active substance: IODIXANOL
    Study summary document link (including results):
    View full study record
    Document reference: 30352
    Study title: Eur Radiol. 1998;8(6):1054-7. Myelography with a dimeric (iodixanol) and a monomeric (iohexol) contrast medium: a clinical multicentre comparative study. Skalpe IO, Bonneville JF, Grane P, Gyldenstedt C, Otto B, Kristoffersen DT, Svaland MG. Eur Radiol. 1998;8(6):1054-7. Myelography with a dimeric (iodixanol) and a monomeric (iohexol) contrast medium: a clinical multicentre comparative study. Skalpe IO, Bonneville JF, Grane P, Gyldenstedt C, Otto B, Kristoffersen DT, Svaland MG.
    Active substance: IOHEXOL
    Study summary document link (including results):
    View full study record
    Document reference: 30372
    Study title: BERATO 1969, DESRUS FOURNIE 1969, REBOUILLAT 1966, WEBER 1986, BADY 1969, GENEVIEVE 1970, GERAUD 1968, GRIMAUD CHEVRIER 1971, 1968, JAROUSSE 1973, BERARD 1969, GILLE 1970, MASSE 1969, PREVOT 1969, VIALLE 1969, SCHILLIRO 1971 - Publications in the Clinical expert report - Dr.A.Hernandez vidal - No date -
    Active substance: TETRAZEPAM
    Study summary document link (including results):
    View full study record
    Document reference: 44480
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 29 23:07:04 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA